Collegium Pharmaceutical (COLL) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Collegium Pharmaceutical (COLL) has outperformed Evotec (EVO) over the past year, losing 34.3% versus a loss of 58.9%. Over five years, COLL leads with a +4.5% price change compared with -92.9% for EVO. Collegium Pharmaceutical is the larger company by market cap ($713.9 million vs $572.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | EVO |
|---|---|---|
| Share price | $21.93 | $1.61 |
| Market cap | $713.94M | $572.18M |
| 1-day change | +0.23% | -1.23% |
| YTD return | -52.63% | -47.73% |
| 1-year return | -34.32% | -58.93% |
| 5-year return | +4.53% | -92.87% |
| P/E ratio (TTM) | 17.27 | — |
| Forward P/E | 3.30 | — |
| EPS (TTM) | $1.27 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $4.27 |
| 52-week low | $21.43 | $1.50 |
| Distance from 52-week high | -56.82% | -62.30% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +123.44% | +158.39% |
| Average volume | 747.73K | 104.15K |
| Shares outstanding | 32.56M | 355.39M |
| Employees | 423 | 4,461 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COLL has outperformed EVO by 24.6 percentage points over the past year.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Healthcare · Drug Manufacturers - Specialty & Generic · 423 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Healthcare · Drug Manufacturers - Specialty & Generic · 4,461 employees
COLL vs EVO FAQ
Which is bigger, Collegium Pharmaceutical or Evotec?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $713.94M compared with $572.18M for Evotec (EVO).
Which stock has performed better over the past year, COLL or EVO?
COLL returned -34.32% over the past 12 months, compared with -58.93% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Evotec in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.